INTERESTING ASSUMPTION!
The observation that Systemic Lupus Erythematosus occurs mostly in female patients to a rate of 8-9:1 over males, and mostly between the age 15 to 44 points to the female reproductive years.  These years are characterized by the reign of Estrogen and its potential suppression of class I Antigen (HLA Antigens) to protect the child from rejection.  We are suggesting that Estrogen would somehow increase epigenic events through Methylation most likely, affects type I Interferon, the destroyer in Lupus, and causes exacerbation of Lupus!
If methylation is that important, Azacytidine could be important in the treatment of Lupus particularly those patient with TET2 Mutation positive ???LET'S GO TO WORK
THE NEW KNOWLEDGE THAT AZACITIDINE HAS IMMUNE IMPLICATION FURTHER SUPPORTS THESE ASSUMPTIONS!